An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

S Drożdżal, J Rosik, K Lechowicz, F Machaj… - Drug Resistance …, 2021 - Elsevier
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and …

DMG Halpin, GJ Criner, A Papi, D Singh… - American journal of …, 2021 - atsjournals.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has raised
many questions about the management of patients with chronic obstructive pulmonary …

[HTML][HTML] Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome

LB Afrin, LB Weinstock, GJ Molderings - International journal of infectious …, 2020 - Elsevier
Abstract Objectives One-fifth of Covid-19 patients suffer a severe course of Covid-19
infection; however, the specific causes remain unclear. Mast cells (MCs) are activated by …

Proposed subtypes of post‐COVID‐19 syndrome (or long‐COVID) and their respective potential therapies

SJ Yong, S Liu - Reviews in medical virology, 2022 - Wiley Online Library
The effects of coronavirus disease 2019 (COVID‐19), a highly transmissible infectious
respiratory disease that has initiated an ongoing pandemic since early 2020, do not always …

Lung fibrosis after COVID-19: treatment prospects

E Bazdyrev, P Rusina, M Panova, F Novikov… - Pharmaceuticals, 2021 - mdpi.com
At the end of 2019, a highly contagious infection began its ominous conquest of the world. It
was soon discovered that the disease was caused by a novel coronavirus designated as …

Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms

P Montero, J Milara, I Roger, J Cortijo - International journal of molecular …, 2021 - mdpi.com
Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by
cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway …

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

S Drożdżal, J Rosik, K Lechowicz, F Machaj… - Drug resistance …, 2020 - Elsevier
In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-
threatening pneumonia in the Hubei province, China, and has now spread worldwide …

The impact of the COVID-19 pandemic on social, health, and economy

VJ Clemente-Suárez, E Navarro-Jiménez… - Sustainability, 2021 - mdpi.com
In late December 2019, a series of acute atypical respiratory disease occurred in Wuhan,
China, which rapidly spread to other areas worldwide. It was soon discovered that a novel …

Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic

SR Ambardar, SL Hightower, NA Huprikar… - Journal of clinical …, 2021 - mdpi.com
Since the initial identification of the novel coronavirus SARS-CoV-2 in December 2019, the
COVID-19 pandemic has become a leading cause of morbidity and mortality worldwide. As …

Pulmonary fibrosis secondary to COVID-19: a narrative review

SE Tanni, AT Fabro, A de Albuquerque… - Expert review of …, 2021 - Taylor & Francis
ABSTRACT Introduction: Coronavirus disease 2019 (COVID-19) is still increasing
worldwide, and as a result, the number of patients with pulmonary fibrosis secondary to …